Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

New Leadership Positions: Joseph Kohles appointed as the group Chief Medical Officer and David Thompson appointed as the group Chief Strategy Officer

Envision Pharma Group
Posted on: 11 Oct 16

Envision Pharma Group ("Envision"), a highly successful Medical Affairs-focused, technology-enabled scientific communications company is delighted to announce two new roles within our leadership team. As we continue to expand our range of services and technology solutions to fully support the Medical Affairs teams within our clients, we have appointed Joseph Kohles and David Thompson, the former leadership team at The Alligent Group (a leading Medical Affairs agency acquired by Envision in September, 2015) to key leadership roles at Envision. 

Dr Joseph Kohles will assume the position of Chief Medical Officer (CMO) to provide medical leadership across the group, provide direction for the development of medical strategy for our clients, provide a peer-to-peer contact for our Medical Affairs clients, and aid in the development/optimization of new technology solutions to support our expanding range of Medical Affairs services. Joe will also head-up a Medical Strategy "think tank" within Envision to provide our clients with leading-edge solutions to the changing demands of the Medical Affairs team and the environment in which they operate.

David Thompson will assume the position of Chief Strategy Officer (CSO) to help drive Envision's continued growth into the leading, global Medical Affairs agency, incorporating expanded multichannel medical communications capabilities, and oversee our expansion into appropriate global locations to facilitate closer proximity to our client base. David will also ensure the continued and improved synergy between our scientific services and supporting technology solutions to maintain Envision’s position as the only medical communications company that encompasses world-class scientific expertise, supported by industry-leading technology solutions to compliantly deliver multichannel medical communication programs. Although responsible for ensuring effective delivery of our scientific services across all 10 of our current global offices, David will be relocating to the UK as part of his new role, and will be based out of our Horsham office for alignment with the existing operational leadership team.

The current leadership team Brian Hepburn (CEO), Greg Caswill (Chairman), Joe Brown (President of Envision Technology Solutions) and John Gillie (CFO) will remain in their existing positions and welcome the augmented structure of leadership team as Envision continue their expansion.

Brian Hepburn, commented, "David and Joe bring incremental strength and depth to the management team, further extending our capabilities and expertise and enhancing our objective of becoming the comprehensive strategic partner to the Medical Affairs departments of our extensive client base."

Envision Pharma Group are still recruiting for open positions at all levels across the organization –

For an informal discussion, or to apply for any of these roles, please contact Karen Kent (

About Envision

Founded in 2001, Envision Pharma Group is an international, innovative global technology and scientific communication company serving pharmaceutical, biotechnology, and medical device companies. Initially focusing on re-inventing the way biopharma companies managed their global data communications programs through the use of smart technology and best-in-class publication planning; Envision has evolved to become a leading provider of evidence communication services and Medical Affairs solutions encompassing all aspects of scientifically-driven data dissemination activities required to support a successful access to market strategy for new biopharma compounds.


This capability of the organization is further enhanced with industry-leading, complementary technology solutions across the Medical Affairs responsibilities. Envision has grown steadily under consistent leadership across its three core business areas in support of the Medical Affairs team that include (i) Evidence Communication – including strategic publication planning, data dissemination services, medical education, and Market Access communications; (ii) Technology Solutions – design, development, implementation, and support of innovative and strategic management software, purpose-built for life-science clients, including, publication planning and management (Datavision®), clearance approval (Clear®), activity request management (Visiontracker®), workflow management for HEOR activities (Visiontracker HEOR™), searchable repository for the sharing of appropriate educational and training materials (Library™), and next generation solution for managing medical information enquiries (Medinfo™); (iii) Consulting Solutions – policy, process, compliance, and guideline consultancy to life-science companies.


Envision currently has ten offices, three in the United Kingdom – Horsham, Wilmslow, and London; five in the United States – Philadelphia, PA, Southport, CT, Madison, NJ, Stirling, NJ, Glastonbury, CT; and two in Asia Pacific – Tokyo and Sydney. The company employs approximately 450 team members, including over 185 highly qualified and experienced in-house medical writers and a more than 80-strong technology solutions team providing platform development and customer support. Envision currently provides service and product solutions to more than 75 client companies, including 18 of the top 20 pharmaceutical companies.

For more information:

Editor's Details

Paul Lane
Envision Pharma Group
01403 322069

Last updated on: 11/10/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.